PURPOSE: To characterize the determinants of variability for oxaliplatin pharmacokinetics including age, renal function, and hepatic function in children and adults. METHODS: Oxaliplatin pharmacokinetic data were combined from phase I and II clinical trials: three pediatric trials (Peds1-3) and two adult NCI organ dysfunction studies (Hepatic and Renal). A population pharmacokinetic model was developed utilizing platinum ultrafiltrate concentrations to characterize changes in oxaliplatin disposition with age and organ dysfunction along with other potential sources of oxaliplatin pharmacokinetic variability. RESULTS: A total of 1,508 concentrations from 186 children and adults were used in the study. The data were well described by a three-compartment model. Serum creatinine (SCR) was an independent predictor of clearance (CL) while age was an independent predictor of volume of distribution. Although age was a significant covariate on CL in the univariate analysis, age effects on CL were entirely accounted for by SCR. Gender, hepatic function, and race had no effect on CL or volume of distribution. Median CL values were 0.58 (Hepatic), 0.34 (Renal), 0.78 (Peds1), 0.74 (Peds2), and 0.81 (Peds3) (L/h/kg(0.75)). Monte Carlo simulations of the final model with 130 mg/m(2) yielded median AUC values of: 14.2 (2-6 years), 16.8 (6-12 years), 16.5 (12-18 years), and 17.3 (>18 years) (µg h/mL). CONCLUSIONS: Renal function had the greatest effect on CL with a small age effect seen on the distribution of oxaliplatin. Young pediatric patients had higher CL values than adults as a result of better renal function.
PURPOSE: To characterize the determinants of variability for oxaliplatin pharmacokinetics including age, renal function, and hepatic function in children and adults. METHODS:Oxaliplatin pharmacokinetic data were combined from phase I and II clinical trials: three pediatric trials (Peds1-3) and two adult NCI organ dysfunction studies (Hepatic and Renal). A population pharmacokinetic model was developed utilizing platinum ultrafiltrate concentrations to characterize changes in oxaliplatin disposition with age and organ dysfunction along with other potential sources of oxaliplatin pharmacokinetic variability. RESULTS: A total of 1,508 concentrations from 186 children and adults were used in the study. The data were well described by a three-compartment model. Serum creatinine (SCR) was an independent predictor of clearance (CL) while age was an independent predictor of volume of distribution. Although age was a significant covariate on CL in the univariate analysis, age effects on CL were entirely accounted for by SCR. Gender, hepatic function, and race had no effect on CL or volume of distribution. Median CL values were 0.58 (Hepatic), 0.34 (Renal), 0.78 (Peds1), 0.74 (Peds2), and 0.81 (Peds3) (L/h/kg(0.75)). Monte Carlo simulations of the final model with 130 mg/m(2) yielded median AUC values of: 14.2 (2-6 years), 16.8 (6-12 years), 16.5 (12-18 years), and 17.3 (>18 years) (µg h/mL). CONCLUSIONS: Renal function had the greatest effect on CL with a small age effect seen on the distribution of oxaliplatin. Young pediatric patients had higher CL values than adults as a result of better renal function.
Authors: Maryam Fouladi; Susan M Blaney; Tina Young Poussaint; Burgess B Freeman; Roger McLendon; Christine Fuller; Adekunle M Adesina; Michael L Hancock; Mary K Danks; Clinton Stewart; James M Boyett; Amar Gajjar Journal: Cancer Date: 2006-11-01 Impact factor: 6.860
Authors: Matthew M Laughon; Daniel K Benjamin; Edmund V Capparelli; Gregory L Kearns; Katherine Berezny; Ian M Paul; Kelly Wade; Jeff Barrett; Phillip Brian Smith; Michael Cohen-Wolkowiez Journal: Expert Rev Clin Pharmacol Date: 2011-09 Impact factor: 5.045
Authors: Orren Beaty; Stacey Berg; Susan Blaney; Marcio Malogolowkin; Mark Krailo; Ronald Knight; Paula Schaiquevich; Clinton Stewart; Zhengjia Chen; Marvin Nelson; Stephan Voss; S Percy Ivy; Peter C Adamson Journal: Pediatr Blood Cancer Date: 2010-09 Impact factor: 3.167
Authors: Timothy W Synold; Chris H Takimoto; James H Doroshow; David Gandara; Sridhar Mani; Scot C Remick; Daniel L Mulkerin; Anne Hamilton; Sunil Sharma; Ramesh K Ramanathan; Heinz Josef Lenz; Martin Graham; Jeffrey Longmate; Bennett M Kaufman; Percy Ivy Journal: Clin Cancer Res Date: 2007-06-15 Impact factor: 12.531
Authors: Sheri L Spunt; Burgess B Freeman; Catherine A Billups; Valerie McPherson; Raja B Khan; Charles B Pratt; Clinton F Stewart Journal: J Clin Oncol Date: 2007-06-01 Impact factor: 44.544
Authors: Chris H Takimoto; Martin A Graham; Graham Lockwood; Chee M Ng; Andrew Goetz; Dennis Greenslade; Scot C Remick; Sunil Sharma; Sridhar Mani; Ramesh K Ramanathan; Timothy W Synold; James H Doroshow; Anne Hamilton; Daniel L Mulkerin; Percy Ivy; Merrill J Egorin; Jean L Grem Journal: Clin Cancer Res Date: 2007-08-15 Impact factor: 12.531
Authors: Anna D Wagner; Axel Grothey; Thierry Andre; Jesse G Dixon; Norman Wolmark; Daniel G Haller; Carmen J Allegra; Aimery de Gramont; Eric VanCutsem; Steven R Alberts; Thomas J George; Michael J O'Connell; Christopher Twelves; Julien Taieb; Leonard B Saltz; Charles D Blanke; Edoardo Francini; Rachel Kerr; Greg Yothers; Jean F Seitz; Silvia Marsoni; Richard M Goldberg; Qian Shi Journal: J Natl Cancer Inst Date: 2021-04-06 Impact factor: 13.506